The Pet Anthelmintic Drugs Market is expected to register a CAGR of 5.5% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The report is segmented by Target Pathogen (Ascaris Lumbricoides [Roundworm], Trichuris Trichiura [Whipworm], Enterobius Vermicularis [Pinworm], Ancylostoma Duodenale [Hookworm], Others); and Distribution Channel (Veterinary Pharmacies, Veterinary Hospitals and Clinics). The global analysis is broken down at the regional level and for major countries. The market evaluation is presented in US$ for the above segmental analysis.
Purpose of the ReportThe report Pet Anthelmintic Drugs Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Pet Anthelmintic Drugs Market Segmentation
Target Pathogen- Ascaris Lumbricoides [Roundworm]
- Trichuris Trichiura [Whipworm]
- Enterobius Vermicularis [Pinworm]
- Ancylostoma Duodenale [Hookworm]
- Veterinary Pharmacies
- Veterinary Hospitals and Clinics
Strategic Insights
Pet Anthelmintic Drugs Market Growth Drivers- Increasing Pet Ownership and Humanization of Pets: One of the primary growth drivers in the Pet Anthelmintic Drugs market is the increasing rate of pet ownership worldwide. People treat their pet animals like family members so they take better care of their health, especially for dogs and cats. People buy more pet healthcare items for their pets including anthelmintic drugs because of this trend. People who treat their pets like family members drive up sales of anthelmintic drugs used to fight parasites. The market for pet anthelmintic drugs will expand because emerging countries will have more pet owners and these owners will need to purchase treatments to protect their animals. The market grows because pet owners understand better how deworming treatments protect their pets from parasites. As pet owners grow in number they will buy more of these products because they want to shield their pets from harm caused by worms and parasites. The pet market grows because more people own pets and spend more money on pet care products, especially in countries where people have higher incomes. Experts predict the pet anthelmintic drug market will keep expanding throughout the next few years in all regions of the world.
- Rising Awareness of Pet Health and Preventive Care: The Pet Anthelmintic Drugs market is expanding because more people understand how to keep their pets healthy. Pet owners now understand how parasites threaten pet health so they take proactive steps to protect their animals through deworming treatments. Vets now recommend preventive treatments more often which makes pet owners buy anthelmintic drugs in large numbers. More pet owners now get their pets dewormed regularly to defend against parasites which is expanding the total market size. Pet owners now choose anthelmintic treatment types more easily because the market offers many options such as pills, chews, and topical medicines. Experts predict additional market growth for pet healthcare products so preventive care will become a main factor in market expansion. Pet owners who understand the serious health problems from untreated parasitic infections will keep getting anthelmintic treatments regularly which supports market expansion.
- Technological Advancements in Drug Development: Modern advancements in medicine help the pet anthelmintic drugs market grow. New drug development methods help pet owners give their animals effective anthelmintic treatment through easier-to-use long-acting medicines. The market expands due to more people choosing pet deworming products because new technology helps these drugs work better. Developers now make drugs that treat various parasite types in one dose which makes these medications more attractive to customers. Due to better pet anthelmintic drugs that work well and are easy to manage, the market keeps getting bigger. The market will expand for companies when they introduce new broad-spectrum anthelmintic drugs to treat multiple parasites. The market will grow steadily because new pet medicine technology keeps improving while veterinarians and pet owners prefer modern treatments for parasites.
- Shift Toward Combination Products: One of the prominent future trends in the Pet Anthelmintic Drugs market is the increasing popularity of combination products. The Pet Anthelmintic Drugs market will see more customers choose combination products in the future. Pet owners want medications that fight different types of parasites at once with easy application methods. People choose combination treatments that fight different parasites in one dose because these products save time and make medication easier to use. Market research shows combination anthelmintic drugs will take up more market space because they protect pets better against multiple parasites. Pet owners now prefer these multi-purpose treatments because they save time by treating multiple types of parasites with a single product. Market predictions show combination therapy use will keep growing because pet owners want better ways to control parasites. The market trend for combination products will grow to take more market share which will change how the industry operates. Companies will develop new all-in-one anthelmintic drugs for pets because consumers want treatments that work effectively and save them time.
- Increased Adoption of Oral and Chewable Anthelmintics: People are moving away from traditional pet worm treatments by using oral and chewable deworming products. Pet owners prefer oral medications as topical treatments because they are now choosing chewable tablets because these products are easier to give to pets and easier for them to swallow. The pet anthelmintic segment will see more of its market growth go to chewable and oral medications because these products make life easier for both pet owners and vets. People choose these medicines because they work better and stay active for longer periods which makes them more popular. The market will see substantial changes in its distribution because consumers are seeking treatments they can use easily and that work well. Market research shows oral anthelmintic medicine will sell more because consumers want treatments that are easy to use and do their job well. The use of oral medications will drive market development especially in developed markets where pet owners invest more in their animals. Modern drug development methods now make chewables taste better and look more appealing to help pet owners choose these treatments. The pet anthelmintic market will expand further as companies gain more buyers and market share from the success of their oral and chewable products.
- Focus on Natural and Organic Pet Medications: More pet owners now want medications derived from natural and organic ingredients to guide pet anthelmintic drug market development. People who care about their health and the environment now want to buy products that look safer and more eco-friendly. People who own pets look for natural and plant-based medicine instead of chemical drugs to treat parasites. The market for natural and plant-based anthelmintic drugs will expand because of this trend. Market data shows organic pet care products such as deworming solutions will keep increasing popularity because pet owners want wellness solutions that match their sustainability values. As pet owners worry about synthetic drug side effects they will use natural and organic anthelmintic drugs more often. The demand for natural parasite prevention products will rise as pet owners prefer these options that work effectively while giving them peace of mind. The market will keep expanding because pet owners want safer products that support the environment.
- Partnerships with Veterinary Clinics and Pet Pharmacies: Strategic partnerships between pharmaceutical companies and veterinary clinics or pet pharmacies present a valuable growth opportunity in the Pet Anthelmintic Drugs market. Companies that partner with veterinary clinics and pet pharmacies gain access to pet owners who depend on their doctors for healthcare recommendations about parasites. Companies strengthen their product exposure when they team up with veterinary clinics and pharmacies which connects them with more pet owners. Veterinary clinics and pet pharmacies will use anthelmintic drugs more often which will boost market share. Through veterinary partnerships pharmaceutical companies can teach pet owners about continuous parasite control and deworming leading to more regular product purchases. Research shows that when veterinary care develops worldwide these collaborations boost market growth by bringing products to more customers and making them trust professional advice.
- Focus on Long-Term Preventive Care Plans: The Pet Anthelmintic Drugs market can grow by introducing preventive care plans that deliver treatment results over extended periods. Pet owners prioritize their pet's health through routine check-ups and preventive care which includes deworming procedures. Pharmaceutical companies can grow their business by creating subscription or long-term treatment plans for anthelmintic drugs that help customers stay regular users and loyal clients. Pet owners who want automatic medicine refills and scheduled medication access can benefit from these plans. Market analysts predict pet anthelmintic sales growth because pet owners will use these drugs more often now that they can access long-term prevention plans. Market studies show businesses will keep using this method because pet owners want streamlined treatments for their pets. By offering subscription services pharmaceutical companies can dominate the market while building dedicated customer relationships which will fuel industry growth.
- Growth in the E-commerce Channel for Pet Medications: Online shopping for pet medications creates a major growth path in the Pet Anthelmintic Drugs market. Internet shopping platforms now serve as primary distribution channels for pet medications including deworming products because many pet owners prefer this method of purchasing. People are moving towards digital platforms to buy pet medications because they offer better prices and easier access plus more convenient shopping. The online retail market will keep expanding because platforms let customers buy everything they need with easy subscription services. The pet healthcare market including anthelmintic drugs will grow mainly through e-commerce outlets according to market size projections. Companies that improve their digital platforms and e-commerce operations will reach more pet owners and expand their customer base. The rise of digital shopping worldwide will push pet anthelmintic products to higher market share and more growth through e-commerce channels.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Pet Anthelmintic Drugs Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Pet Anthelmintic Drugs Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?

Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities

Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
This text is related
to segments covered.

Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Pet Anthelmintic Drugs Market is estimated to witness a CAGR of 5.5% from 2025 to 2031.
The major factors driving the Pet Anthelmintic Drugs Market are Increasing Pet Ownership and Humanization of Pets, Rising Awareness of Pet Health and Preventive Care, and Technological Advancements in Drug Development
Future trends in the Pet Anthelmintic Drugs Market are Shift Toward Combination Products, Increased Adoption of Oral and Chewable Anthelmintics, and Focus on Natural and Organic Pet Medications.
Some of the players operating in the market are Novartis AG, Cipla Inc., Sun Pharmaceutical Industries Ltd, Amneal Pharmaceuticals LLC. (Impax Laboratories, Inc.), Zoetis, Inc., GlaxoSmithKline plc, Bayer AG, Merck & Co., Inc. (Intervet Inc.), Boehringer Ingelheim International GmbH, Virbac.
The report can be delivered in PDF/PPT format; we can also share an excel datasheet based on the request.
Some customization options available based on the request are an additional 3–5 company profiles and a country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation# as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Pet Anthelmintic Drugs Market - By Target Pathogen
1.3.2 Pet Anthelmintic Drugs Market - By Distribution Channel
1.3.3 Pet Anthelmintic Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. PET ANTHELMINTIC DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. PET ANTHELMINTIC DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. PET ANTHELMINTIC DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. PET ANTHELMINTIC DRUGS - GLOBAL MARKET OVERVIEW
6.2. PET ANTHELMINTIC DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. PET ANTHELMINTIC DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - TARGET PATHOGEN
7.1. OVERVIEW
7.2. TARGET PATHOGEN MARKET FORECASTS AND ANALYSIS
7.3. ASCARIS LUMBRICOIDES [ROUNDWORM]
7.3.1. Overview
7.3.2. Ascaris Lumbricoides [Roundworm] Market Forecast and Analysis
7.4. TRICHURIS TRICHIURA [WHIPWORM]
7.4.1. Overview
7.4.2. Trichuris Trichiura [Whipworm] Market Forecast and Analysis
7.5. ENTEROBIUS VERMICULARIS [PINWORM]
7.5.1. Overview
7.5.2. Enterobius Vermicularis [Pinworm] Market Forecast and Analysis
7.6. ANCYLOSTOMA DUODENALE [HOOKWORM]
7.6.1. Overview
7.6.2. Ancylostoma Duodenale [Hookworm] Market Forecast and Analysis
7.7. OTHERS
7.7.1. Overview
7.7.2. Others Market Forecast and Analysis
8. PET ANTHELMINTIC DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
8.1. OVERVIEW
8.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
8.3. VETERINARY PHARMACIES
8.3.1. Overview
8.3.2. Veterinary Pharmacies Market Forecast and Analysis
8.4. VETERINARY HOSPITALS AND CLINICS
8.4.1. Overview
8.4.2. Veterinary Hospitals and Clinics Market Forecast and Analysis
9. PET ANTHELMINTIC DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Pet Anthelmintic Drugs Market Overview
9.1.2 North America Pet Anthelmintic Drugs Market Forecasts and Analysis
9.1.3 North America Pet Anthelmintic Drugs Market Forecasts and Analysis - By Target Pathogen
9.1.4 North America Pet Anthelmintic Drugs Market Forecasts and Analysis - By Distribution Channel
9.1.5 North America Pet Anthelmintic Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States Pet Anthelmintic Drugs Market
9.1.5.1.1 United States Pet Anthelmintic Drugs Market by Target Pathogen
9.1.5.1.2 United States Pet Anthelmintic Drugs Market by Distribution Channel
9.1.5.2 Canada Pet Anthelmintic Drugs Market
9.1.5.2.1 Canada Pet Anthelmintic Drugs Market by Target Pathogen
9.1.5.2.2 Canada Pet Anthelmintic Drugs Market by Distribution Channel
9.1.5.3 Mexico Pet Anthelmintic Drugs Market
9.1.5.3.1 Mexico Pet Anthelmintic Drugs Market by Target Pathogen
9.1.5.3.2 Mexico Pet Anthelmintic Drugs Market by Distribution Channel
9.2. EUROPE
9.2.1 Europe Pet Anthelmintic Drugs Market Overview
9.2.2 Europe Pet Anthelmintic Drugs Market Forecasts and Analysis
9.2.3 Europe Pet Anthelmintic Drugs Market Forecasts and Analysis - By Target Pathogen
9.2.4 Europe Pet Anthelmintic Drugs Market Forecasts and Analysis - By Distribution Channel
9.2.5 Europe Pet Anthelmintic Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Pet Anthelmintic Drugs Market
9.2.5.1.1 Germany Pet Anthelmintic Drugs Market by Target Pathogen
9.2.5.1.2 Germany Pet Anthelmintic Drugs Market by Distribution Channel
9.2.5.2 France Pet Anthelmintic Drugs Market
9.2.5.2.1 France Pet Anthelmintic Drugs Market by Target Pathogen
9.2.5.2.2 France Pet Anthelmintic Drugs Market by Distribution Channel
9.2.5.3 Italy Pet Anthelmintic Drugs Market
9.2.5.3.1 Italy Pet Anthelmintic Drugs Market by Target Pathogen
9.2.5.3.2 Italy Pet Anthelmintic Drugs Market by Distribution Channel
9.2.5.4 Spain Pet Anthelmintic Drugs Market
9.2.5.4.1 Spain Pet Anthelmintic Drugs Market by Target Pathogen
9.2.5.4.2 Spain Pet Anthelmintic Drugs Market by Distribution Channel
9.2.5.5 United Kingdom Pet Anthelmintic Drugs Market
9.2.5.5.1 United Kingdom Pet Anthelmintic Drugs Market by Target Pathogen
9.2.5.5.2 United Kingdom Pet Anthelmintic Drugs Market by Distribution Channel
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Pet Anthelmintic Drugs Market Overview
9.3.2 Asia-Pacific Pet Anthelmintic Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Pet Anthelmintic Drugs Market Forecasts and Analysis - By Target Pathogen
9.3.4 Asia-Pacific Pet Anthelmintic Drugs Market Forecasts and Analysis - By Distribution Channel
9.3.5 Asia-Pacific Pet Anthelmintic Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Pet Anthelmintic Drugs Market
9.3.5.1.1 Australia Pet Anthelmintic Drugs Market by Target Pathogen
9.3.5.1.2 Australia Pet Anthelmintic Drugs Market by Distribution Channel
9.3.5.2 China Pet Anthelmintic Drugs Market
9.3.5.2.1 China Pet Anthelmintic Drugs Market by Target Pathogen
9.3.5.2.2 China Pet Anthelmintic Drugs Market by Distribution Channel
9.3.5.3 India Pet Anthelmintic Drugs Market
9.3.5.3.1 India Pet Anthelmintic Drugs Market by Target Pathogen
9.3.5.3.2 India Pet Anthelmintic Drugs Market by Distribution Channel
9.3.5.4 Japan Pet Anthelmintic Drugs Market
9.3.5.4.1 Japan Pet Anthelmintic Drugs Market by Target Pathogen
9.3.5.4.2 Japan Pet Anthelmintic Drugs Market by Distribution Channel
9.3.5.5 South Korea Pet Anthelmintic Drugs Market
9.3.5.5.1 South Korea Pet Anthelmintic Drugs Market by Target Pathogen
9.3.5.5.2 South Korea Pet Anthelmintic Drugs Market by Distribution Channel
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Pet Anthelmintic Drugs Market Overview
9.4.2 Middle East and Africa Pet Anthelmintic Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Pet Anthelmintic Drugs Market Forecasts and Analysis - By Target Pathogen
9.4.4 Middle East and Africa Pet Anthelmintic Drugs Market Forecasts and Analysis - By Distribution Channel
9.4.5 Middle East and Africa Pet Anthelmintic Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Pet Anthelmintic Drugs Market
9.4.5.1.1 South Africa Pet Anthelmintic Drugs Market by Target Pathogen
9.4.5.1.2 South Africa Pet Anthelmintic Drugs Market by Distribution Channel
9.4.5.2 Saudi Arabia Pet Anthelmintic Drugs Market
9.4.5.2.1 Saudi Arabia Pet Anthelmintic Drugs Market by Target Pathogen
9.4.5.2.2 Saudi Arabia Pet Anthelmintic Drugs Market by Distribution Channel
9.4.5.3 U.A.E Pet Anthelmintic Drugs Market
9.4.5.3.1 U.A.E Pet Anthelmintic Drugs Market by Target Pathogen
9.4.5.3.2 U.A.E Pet Anthelmintic Drugs Market by Distribution Channel
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Pet Anthelmintic Drugs Market Overview
9.5.2 South and Central America Pet Anthelmintic Drugs Market Forecasts and Analysis
9.5.3 South and Central America Pet Anthelmintic Drugs Market Forecasts and Analysis - By Target Pathogen
9.5.4 South and Central America Pet Anthelmintic Drugs Market Forecasts and Analysis - By Distribution Channel
9.5.5 South and Central America Pet Anthelmintic Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Pet Anthelmintic Drugs Market
9.5.5.1.1 Brazil Pet Anthelmintic Drugs Market by Target Pathogen
9.5.5.1.2 Brazil Pet Anthelmintic Drugs Market by Distribution Channel
9.5.5.2 Argentina Pet Anthelmintic Drugs Market
9.5.5.2.1 Argentina Pet Anthelmintic Drugs Market by Target Pathogen
9.5.5.2.2 Argentina Pet Anthelmintic Drugs Market by Distribution Channel
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL PET ANTHELMINTIC DRUGS MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Rest of the World
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. PET ANTHELMINTIC DRUGS MARKET, KEY COMPANY PROFILES
12.1. NOVARTIS AG
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. CIPLA INC.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. SUN PHARMACEUTICAL INDUSTRIES LTD
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. AMNEAL PHARMACEUTICALS LLC. (IMPAX LABORATORIES, INC.)
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. ZOETIS, INC.
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. GLAXOSMITHKLINE PLC
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. BAYER AG
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. MERCK AND CO., INC. (INTERVET INC.)
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. BOEHRINGER INGELHEIM INTERNATIONAL GMBH
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. VIRBAC
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
12.11.
12.11.1. Key Facts
12.11.2. Business Description
12.11.3. Products and Services
12.11.4. Financial Overview
12.11.5. SWOT Analysis
12.11.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
1. Novartis AG
2. Cipla Inc.
3. Sun Pharmaceutical Industries Ltd
4. Amneal Pharmaceuticals LLC. (Impax Laboratories, Inc.)
5. Zoetis, Inc.
6. GlaxoSmithKline plc
7. Bayer AG
8. Merck & Co., Inc. (Intervet Inc.)
9. Boehringer Ingelheim International GmbH
10. Virbac
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.